| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
89,554,000 |
| Market
Cap: |
2.19(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$20.02 - $46.03 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Intellia Therapeutics is a genome editing company focused on developing therapeutics using CRISPR/Cas9 technology. CRISPR/Cas9, an acronym for Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9), is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (DNA). To realize the transformative potential of CRISPR/Cas9-based technologies, Co. is building a range of genome editing company, by utilizing its modular platform, to advance in vivo and ex vivo therapies for diseases with high unmet need.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
2,902 |
53,430 |
61,187 |
62,275 |
| Total Sell Value |
$95,737 |
$1,583,155 |
$1,913,663 |
$1,961,404 |
| Total People Sold |
2 |
7 |
8 |
8 |
| Total Sell Transactions |
2 |
10 |
15 |
16 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Formela Jean Francois |
Director |
– • – |
2017-03-10 |
4 |
S |
$14.06 |
$77,410 |
I/I |
(5,504) |
0 |
|
- |
|
| Atlas Venture Associates Ix, Llc |
10% Owner |
– – • |
2017-03-09 |
4 |
S |
$13.85 |
$216,432 |
D/D |
(15,628) |
5,504 |
|
- |
|
| Formela Jean Francois |
Director |
– • – |
2017-03-09 |
4 |
S |
$13.85 |
$216,432 |
I/I |
(15,628) |
5,504 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2017-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
79,245 |
5,652,903 |
|
- |
|
| Atlas Venture Associates Ix, Llc |
10% Owner |
– – • |
2017-03-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(700,000) |
3,729,788 |
|
- |
|
| Isaly Samuel D |
Director |
– • – |
2016-05-11 |
4 |
B |
$18.00 |
$4,500,000 |
I/I |
250,000 |
2,662,180 |
2.1 |
- |
|
| Isaly Samuel D |
Director |
– • – |
2016-05-11 |
4 |
A |
$0.00 |
$0 |
I/I |
2,412,180 |
2,412,180 |
|
- |
|
| Tls Beta Pte. Ltd. |
10% Owner |
– – • |
2016-05-11 |
4 |
B |
$18.00 |
$5,400,000 |
I/I |
300,000 |
790,527 |
1.5 |
- |
|
| Tls Beta Pte. Ltd. |
10% Owner |
– – • |
2016-05-11 |
4 |
A |
$0.00 |
$0 |
I/I |
490,527 |
490,527 |
|
- |
|
| Baker Bros. Advisors (gp) Llc |
Former 10% owner |
– – – |
2016-05-11 |
4 |
B |
$18.00 |
$3,600,000 |
I/I |
200,000 |
976,214 |
0.01 |
- |
|
| Baker Bros. Advisors (gp) Llc |
Former 10% owner |
– – – |
2016-05-11 |
4 |
A |
$0.00 |
$0 |
I/I |
862,120 |
796,683 |
|
- |
|
| Formela Jean Francois |
Director |
– • – |
2016-05-11 |
4 |
A |
$0.00 |
$0 |
I/I |
4,429,788 |
4,429,788 |
|
- |
|
| Atlas Venture Associates Ix, Llc |
10% Owner |
– – • |
2016-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
4,429,788 |
4,429,788 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2016-05-11 |
4 |
B |
$18.00 |
$4,999,986 |
D/D |
277,777 |
5,573,658 |
2.45 |
- |
|
| Novartis Ag |
10% Owner |
– – • |
2016-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
5,295,881 |
5,295,881 |
|
- |
|
| Haurwitz Rachel E. |
Director |
– • • |
2016-05-11 |
4 |
A |
$0.00 |
$0 |
I/I |
5,419,040 |
5,593,846 |
|
- |
|
| Gordon Carl L |
Director |
– • – |
2016-05-11 |
4 |
B |
$18.00 |
$4,500,000 |
I/I |
250,000 |
2,662,180 |
2.1 |
- |
|
| Gordon Carl L |
Director |
– • – |
2016-05-11 |
4 |
A |
$0.00 |
$0 |
I/I |
2,412,180 |
2,412,180 |
|
- |
|
| Caribou Biosciences, Inc. |
10% Owner |
– – • |
2016-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
5,419,040 |
5,593,846 |
|
- |
|
| Bermingham Nessan |
President & CEO |
• • – |
2016-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
437,019 |
786,633 |
|
- |
|
245 Records found
|
|
Page 10 of 10 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.40 (1.61%) 
